This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Ultragenyx said Thursday it will cut 130 jobs, or 10% of its workforce, as part of a corporate restructuring intended to support profitability in 2027, driven by revenue growth from its portfolio of rare disease drugs. The restructuring will keep expenses flat or slightly down in 2026 compared with 2025, which will include around $50 million in r ...